Cargando…

Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence

We determined the mitogen-activated protein kinase (MAPK) gene expression profile of acquired resistance in sorafenib-sensitive hepatocellular carcinoma (HCC) cells and aimed to identify c-Jun as an important molecule mediating the efficacy of sorafenib. Differences in gene expression of the MAPK si...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Wei, Xiao, Weikai, Zhang, Kunsong, Yin, Xiaoyu, Lai, Jiaming, Liang, Lijian, Chen, Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786823/ https://www.ncbi.nlm.nih.gov/pubmed/26964667 http://dx.doi.org/10.1038/srep22976

Ejemplares similares

Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines
por: Haga, Yuki, et al.
Publicado: (2017)

Overexpression of SEZ6L2 predicts poor prognosis in patients with cholangiocarcinoma
por: Wang, Ziming, et al.
Publicado: (2020)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
por: Marconato, Laura, et al.
Publicado: (2020)

Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study
por: He, Wei, et al.
Publicado: (2020)

Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma
por: Zhao, Yang, et al.
Publicado: (2019)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma
por: Hu, Xinyao, et al.
Publicado: (2021)

The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma
por: Wu, Fei-Xiang, et al.
Publicado: (2017)

TARBP2‐mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma
por: Lai, Hui‐Huang, et al.
Publicado: (2019)

Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma
por: Liang, Kung-Hao, et al.
Publicado: (2021)

Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy
por: Ni, Jia-Yan, et al.
Publicado: (2019)

Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Li, Yan, et al.
Publicado: (2022)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
por: Xia, Shunjie, et al.
Publicado: (2020)

Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
por: Lai, Yongting, et al.
Publicado: (2019)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma
por: Saif, Muhammad W., et al.
Publicado: (2011)

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
por: Almhanna, Khaldoun, et al.
Publicado: (2009)

Evolving role of Sorafenib in the management of hepatocellular carcinoma
por: Ziogas, Ioannis A, et al.
Publicado: (2017)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
por: Ko, Yi-Ling, et al.
Publicado: (2020)

Corrigendum: Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
por: Lai, Yongting, et al.
Publicado: (2020)

A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function
por: Yang, Hyun, et al.
Publicado: (2017)

A micropeptide JunBP regulated by TGF-β promotes hepatocellular carcinoma metastasis
por: Zhang, Hongwei, et al.
Publicado: (2022)

AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest
por: Zhou, Wei, et al.
Publicado: (2021)

The Roles Of Angiogenesis And Cancer Stem Cells In Sorafenib Drug Resistance In Hepatocellular Carcinoma
por: Cheng, Chiung-Chi, et al.
Publicado: (2019)

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma
por: Liu, Kai-Cai, et al.
Publicado: (2020)

Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma
por: Liang, Yuelong, et al.
Publicado: (2017)

Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases
por: Liu, Mingyu, et al.
Publicado: (2023)

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma
por: Hagiwara, S, et al.
Publicado: (2012)

Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma
por: Imai, Kenji, et al.
Publicado: (2020)

The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Chen, Lei, et al.
Publicado: (2021)

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017)

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
por: Huang, Wei-Chien, et al.
Publicado: (2013)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

Acalculous Cholecystitis in a Patient with Hepatocellular Carcinoma on Sorafenib
por: Sanda, Mariko, et al.
Publicado: (2011)

Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib
por: Barbier, L., et al.
Publicado: (2011)

Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_u3ghktmas25bfotthl06plp8u3